X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Biocon: Precursor to the research report - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Jul 12, 2004

    Biocon: Precursor to the research report

    Biocon is India's largest Biotechnology company with presence in biopharmaceuticals, enzymes, custom research and clinical research. It is a leading player in supply of simvastatin (a bulk drug) in the European markets (39% of sales). Let us take a review of the company.

    Biocon is an integrated pharma company, which is involved into drug discovery, clinical development, drug manufacturing and sales. Its two subsidiaries, Syngene (drug discovery) and Clingene (clinical development), are working towards developing new drugs in the biopharmaceutical space.

    The major source of revenue for Biocon is statins (a type of molecule), which constituted 56% of consolidated revenues in FY04. Statins are the largest selling class of drugs in the world, which inhibits the excess production of bad cholesterol in the liver. The total market size of statins is about US$ 25 bn and is likely to grow at a rate of 18% in FY05. Although the major molecule in the statins category is Atorvastatin (a value-add statin drug), it is yet to come off patent in the regulated market. The presence of Biocon in this high growth segment is the key to its future growth. Although the company has achieved a great success in these molecules (90% growth over the last 3 years), going forward, it will be an uphill task due to intensifying competition (Lupin and Ranbaxy has the same cost advantage as Biocon).

    Another focus area for the company has been the anti-diabetic segment. Biocon is launching an indigenously developed human insulin product (Insugen) in the Indian market by the second quarter of FY05 under its own brand name. This will be its first product in the Indian markets. The company has also signed an agreement with Bristol-Myers Squibb to supply human insulin in bulk form to markets like the US. There are several other products in the company's portfolio in the anti-diabetic segment.

    Let us look at the financial performance of the company. The sales of the company grew by 94% in FY04 on back of strong growth in the export revenue basically (statins and custom research services). The net profit grew three times due to increase in net profit margins (higher realisation on exports and overall operational efficiency).

    The company has been seen as the pioneer of biopharmaceutical in the country, which is based on innovation and creativity. The success till date was basically driven by technology driven products and mainly into the bulk market. The high dependency on key products like statins (56% of sales) increases the risk profile of the company. Going forward, we might see some product launches from the company in the domestic market under its own brand name. This will post a real challenge of establishing the brand name, franchise and distribution channel for the company.

    The stock currently trades at Rs 555 at a P/E multiple of 40x its FY04 earnings.

     

     

    Equitymaster requests your view! Post a comment on "Biocon: Precursor to the research report". Click here!

      
     

    More Views on News

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

    Nov 7, 2016

    Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

    Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    BIOCON LTD SHARE PRICE


    Aug 22, 2017 (Close)

    TRACK BIOCON LTD

    • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    BIOCON LTD 8-QTR ANALYSIS

    Detailed Quarterly Results With Charts

    COMPARE BIOCON LTD WITH

    MARKET STATS